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The human body is the residence of a large number of commensal (non-pathogenic)
and pathogenic microbial species that have co-evolved with the human genome,
adaptive immune system, and diet. With recent advances in DNA-based technologies,
we initiated the exploration of bacterial gene functions and their role in human health. The
main goal of the human microbiome project is to characterize the abundance, diversity
and functionality of the genes present in all microorganisms that permanently live in
different sites of the human body. The gut microbiota expresses over 3.3 million bacterial
genes, while the human genome expresses only 20 thousand genes. Microbe gene-
products exert pivotal functions via the regulation of food digestion and immune system
development. Studies are confirming that manipulation of non-pathogenic bacterial
strains in the host can stimulate the recovery of the immune response to pathogenic
bacteria causing diseases. Different approaches, including the use of nutraceutics
(prebiotics and probiotics) as well as phages engineered with CRISPR/Cas systems
and quorum sensing systems have been developed as new therapies for controlling
dysbiosis (alterations in microbial community) and common diseases (e.g., diabetes and
obesity). The designing and production of pharmaceuticals based on our own body’s
microbiome is an emerging field and is rapidly growing to be fully explored in the near
future. This review provides an outlook on recent findings on the human microbiomes,
their impact on health and diseases, and on the development of targeted therapies.
Keywords: microbiome, metagenomics, phage therapy, CRISPR/Cas system, quorum sensing,
pharmacomicrobiomics
Introduction
The evolution of Homo sapiens is linked to a mutualistic partnership with the human gut
microbiota. The human genome is part of a collective genome of complex commensal, symbiotic,
and pathogenic microbial community that colonizes the human body. Our microbiome includes
not only bacteria, but also viruses, protozoans, and fungi (Backhed et al., 2012). Bacteria are a
vast group of living organisms considered a domain of life in themselves (Woese et al., 1990).
They are classiﬁed using DNA-based tests, morphologically and biochemically based on cell wall
type, cell shape, oxygen requirements, endospore production, motility, and energy requirements.
Hans Christian Gram (1850–1938), a Danish scientist, discovered that the presence of high levels
of peptidoglycan (50–90%) produced a dark violet color, while low levels (<10%) resulted in
reddish/pinkish colors, which are the respective staining of Gram-positive and Gram-negative
bacteria. The Gram-negative cell wall is also characterized by the presence of lipopolysaccharides
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(LPSs). Based on their capacity to produce energy in presence
or absence of oxygen, bacteria can also be classiﬁed as aerobic,
anaerobic or facultative anaerobic. In addition to the generation
of ATP via aerobic or anaerobic respiration, bacteria can also
produce energy via fermentation. Facultative anaerobic bacteria
are able to generate ATP with or without oxygen, while obligated
anaerobic bacteria do not tolerate it and only survive in
anaerobiosis. Lactobacillus, Staphylococcus, and Escherichia coli
are examples of facultative anaerobic bacteria. Bacteroides, on
the other hand, are obligated anaerobic species. In inﬂamed
tissues, the enterocytes produce reactive oxygen species (ROS)
and kill anaerobic bacteria increasing the abundance of aerobic
and facultative species.
Bacteria are classiﬁed phylogenetically based on the analysis of
nucleotide sequences of small subunit ribosomal RNA operons,
mainly variable regions of the bacterial speciﬁc ribosomal RNA,
16S rRNA (Woese, 1987; Woese et al., 1990; Marchesi et al.,
1998). Currently, the Bacteria domain is divided into many
phyla; however, the majority of microbes forming the human
microbiota can be assigned to four major phyla: Firmicutes,
Bacteroidetes, Actinobacteria, and Proteobacteria (Zoetendal
et al., 2008; Arumugam et al., 2011; Segata et al., 2012). Firmicutes
and Bacteroidetes represent more than 90% of the relative
abundance of the gut microbiome (Arumugam et al., 2011; Segata
et al., 2012). Firmicutes are a diverse phylum composed mainly
of the Bacilli and Clostridia classes. They are Gram-positive,
anaerobic (Clostridia) and obligate or facultative aerobes (Bacilli)
characterized by a low GC content. Bacteria of Clostridium
species produce endospores in order to survive to adverse
(aerobic) conditions (Paredes-Sabja et al., 2014). The phylum
Bacteroidetes is composed of Gram-negative, non-spore forming
anaerobic bacteria that tolerate the presence of oxygen but cannot
use it for growth. Actinobacteria (e.g., Biﬁdobacterium) are
Gram-positive, multiple branching rods, non-motile, non-spore-
forming, and anaerobic bacteria. Proteobacteria (e.g., Escherichia,
Klebsiella, Enterobacter) are aerobic or facultative anaerobic,
Gram-negative, non-spore-forming rod bacteria, which inhabit
the intestinal tract of all vertebrates.
Recent survey studies on the variation of human microbiomes
concluded that European individuals could be classiﬁed in up to
three enterotypes based on 16S rRNA gene data and functional
metagenome (whole genome shotgun) data (Arumugam et al.,
2011; Koren et al., 2013). An enterotype refers to the relative
abundance of speciﬁc bacterial taxa within the gut microbiomes
of humans. The functional metagenome of each enterotype
revealed diﬀerences in the proportions of genes involved in
carbohydrate versus protein metabolism, which is consistent with
diets of diﬀerent populations (Arumugam et al., 2011; Koren
et al., 2013). People diﬀer by species composition, distribution,
diversity, and numbers of bacteria (Yatsunenko et al., 2012).
The dietary habits are the critical contributing factor. Diversity
(microbiome variation and complexity) increases from birth
and reaches its highest point in early adulthood, thereafter
declining with old age. However, larger longitudinal studies that
include more populations, such as South Americans, Indians
and Africans need to be done to identify the actual structure
and biological impact of the distinct human microbiomes.
These studies may also reveal how evolution of life-styles
modulated ancestral and modern human microbiomes. Here
we will present and discuss recent advances of microbiome
studies and the strategies for the development of innovative
pharmaceuticals based on emerging population and individual
microbiota genomic information.
Metagenomics
The recent development of next generation sequencing (NGS)
technologies such as 454, Solexa/Illumina, Ion Torrent and
Ion Proton sequencers and the parallel expansion of powerful
bioinformatics programs made possible the genomic analysis of
over 1,000 prokaryotic and 100 eukaryotic organisms, including
over 1,200 complete human genomes (Flintoft, 2012; Belizario,
2013). Metagenomics is a biotechnological approach to study
genomic sequences of uncultivated microbes directly from
their natural sources (Wooley et al., 2010). This allows the
simultaneous analysis of microbial diversity connecting it to
speciﬁc functions in diﬀerent environments, such as soil, marine
environments, and human body habitats (Ley et al., 2008;
Robinson et al., 2010; Culligan et al., 2014). Using these novel
methods, scientists have provided evidence for the existence
of more than one thousand microorganism species living in
our body (Arumugam et al., 2011; Segata et al., 2012) and an
estimation of 107 to 109 diﬀerent species of bacteria living on
earth (Curtis et al., 2002). More important, the metagenomics
approach has the potential to uncover entirely novel genes,
gene families, and their encoded proteins, which might be of
biotechnological and pharmaceutical relevance.
Currently several international projects aimed at the
characterization of the human microbiota are being carried
out. The Human Microbiome Project (HMP) is a research
initiative of the National Institute of Health (NIH) in the United
States, which aims to characterize the microbial communities
found in several diﬀerent sites of the human body (Turnbaugh
et al., 2007; Backhed et al., 2012; Human Microbiome Project,
2012a,b). MetaHIT (Metagenomics of the Human Intestinal
Tract) is a project ﬁnanced by the European Commission and
is under management of a consortium of 13 European partners
from academia and the industry. The International Human
Microbiome Consortium (IHMC) is composed of European,
Canadian, Chinese, and US scientiﬁc institutions1.
A simple molecular approach to explore the microbial
diversity is based on the analysis of variable regions of 16S
rRNA gene using “universal” primers which are complementary
to highly conserved sequences among the homologous 16S rRNA
genes (Marchesi et al., 1998; Culligan et al., 2014). These genes
contain nine hypervariable regions (V1–V9) whose sequence
diversity is appropriated for characterizing bacterial community
compositions in complex samples (Guo et al., 2013; Jiang et al.,
2014; Montassier et al., 2014). DNA sequences obtained with
this approach can be mapped onto a reference set of known
bacterial genomes. For this purpose useful bioinformatics tools
1http://www.human-microbiome.org/
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and databases are available. For example, the SILVA database2
is a comprehensive online resource for quality checked and
aligned ribosomal RNA sequence data that helps determine an
optimal alignment for the diﬀerent sequence regions (Pruesse
et al., 2007). First released in 1995, The Ribosomal Database
Project (RDP) is another database that provides high quality
alignments of archaeal and bacterial 16S rRNA sequences as
well as fungal 28S rRNA sequences (Maidak et al., 1996). The
microbial proﬁling and phylogenetic clustering of microbiomes
of the American and European population have been already
deposited and are free for consultation3 ,4. The HMP projects and
other independent projects have been generating an enormous
amount of metagenomic data and the assemblies of microbiome
data is being undertaken by the Genomes OnLine Database5.
The data management system for cataloging and continuous
monitoring of worldwide sequencing projects contains data from
over 4000 metagenome sequencing projects, in which more
than 1500 are aimed at the characterization of host associated
metagenomes (Human Microbiome Jumpstart Reference Strains
et al., 2010; Fodor et al., 2012; Reddy et al., 2015).
The ﬁrst release of the HMP database included microbiome
data of nasal passages, the oral cavity, skin, gastrointestinal
tract, and urogenital tract (HumanMicrobiome Project, 2012a,b).
Figure 1 schematically summarizes the data of these studies. The
results of over 690 human microbiomes have shown that the
majority of bacteria of the gut microbiome belongs to four phyla:
Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria
(Human Microbiome Project, 2012a,b). Only a fraction of
microbes identiﬁed so far have been successfully cultured, and
thousands are yet to be fully sequenced for a deeper taxonomic
resolution (strains and subspecies) and functional analysis at the
genomic level (Qin et al., 2010; Robinson et al., 2010; Abubucker
et al., 2012; Flintoft, 2012; Zhou et al., 2013).
The metagenome wide association studies in development in
many countries are promising in predicting new diagnostic and
prognostic tools for numerous human disorders. The results of
these studies will dramatically increase our knowledge of diseases
linked to microbial composition (Qin et al., 2010; Clemente
et al., 2012; Flintoft, 2012; Gevers et al., 2012). In order to better
understand the host-gene-microbial interactions and the role
of non-pathogenic and pathogenic strains in large populations,
we need to compare microbiome proﬁles across multiple body
sites and microbiome datasets under environmentally controlled
normal and disease conditions. In the following sections, we
will provide a synthesis of the recent studies on the human
microbiomes identiﬁed in some major body sites.
Gut Microbiome
The HMPs have shown that the human gut harbors one of
the most complex and abundant ecosystems colonized by more
than 100 trillion microorganisms (Human Microbiome Project,
2012a,b). In adults, the majority of the bacteria found in the gut
2http://www.arb-silva.de
3http://www.metahit.eu/
4http://www.hmpdacc.org/
5http://www.genomesonline.org
belong to two bacterial phyla, the gram-negative Bacteroidetes
and the gram-positive, Firmicutes; and the others represented
at subdominant levels are the Actinobacteria, Fusobacteria, and
Verrucomicrobia phyla, but this varies dramatically among
individuals (Eckburg et al., 2005; Zoetendal et al., 2008;
Arumugam et al., 2011; Backhed et al., 2012; Segata et al., 2012).
For instance, the most abundant genera from the Bacteroidetes
phylum are Bacteroides and Prevotella species, which represent
80% of all Bacteroidetes in fecal samples. Nonetheless, many
of the taxa numerically underrepresented and less-abundant
bacterial species exert fundamental functions at a particular
location in the gut. To better deﬁne these diﬀerent microbial
colonization and microbiota structure in diﬀerent cohorts arose
the concept of ‘enterotype clusters’ that allow the classiﬁcation
of each individual based on the relative abundance of speciﬁc
bacterial taxa in fecal samples, and their microbial metabolic
and functional pathways (Arumugam et al., 2011; Backhed
et al., 2012; Koren et al., 2013). The results of metagenomic
sequencing of fecal samples from European, American, and
Japanese subjects conﬁrmed the three robust clusters dominated
by Bacteroides (enterotype 1), Prevotella (enterotype 2), and
Ruminococcus (enterotype 3), each one characterized by speciﬁc
taxonomic composition and relative abundance of metabolic
pathways. For example, enterotype 1 was enriched in biosynthesis
of biotin, riboﬂavin pantothenate and ascorbate; enterotype 2
in biosynthesis of thiamine and folate. Enterotype 3 showed
high abundance of genes involved in haem biosynthesis pathway.
Although in one of these studies (Arumugam et al., 2011) it
was conﬁrmed that a set of 12 genes correlated with age and
a set of three functional modules with the body mass index
(BMI), further studies will be required to determine if speciﬁc
microbiome and/or enterotype is associated with gender, BMI,
health status, diet, and age of individuals (Arumugam et al., 2011;
Backhed et al., 2012; Koren et al., 2013).
Although stable over long periods, the composition and
functions of the gut microbiome may be inﬂuenced by a
number of factors including genetics, mode of delivery, age, diet,
geographic location, and medical treatments (Clemente et al.,
2012; Brown et al., 2013). The intestinal microbiota is acquired
in the postnatal periods of time, consisting of a wide variety
of bacteria that plays diﬀerent functions in the human host,
including nutrient absorption, protection against pathogens, and
modulation of the immune system (Brown et al., 2013). The
gut is an anaerobic environment in which indigenous species
have co-evolved with the host. The aerobic pathogenic species
cannot invade and colonize it; however, anaerobic and facultative
pathogenic species can invade it causing diseases. High diversity
deﬁnes healthy human gut microbiomes, whereas reduction in
diversity may be associated with dysbiosis (Manichanh et al.,
2006; Backhed et al., 2012). Dysbiosis refers to an imbalance in
the microbiome structure that results from an abnormal ratio
of commensal and pathogenic bacterial species. Many studies
have suggested a possible direct relationship between dysbiosis
and inﬂammatory andmetabolic diseases such as is inﬂammatory
bowel diseases (IBD) including colitis and Crohn’s disease (CD),
obesity and cancer (Clemente et al., 2012; Sartor andMazmanian,
2012; Brown et al., 2013). However, investigation of such a
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FIGURE 1 | Taxonomic distribution, prevalence and abundance of microbial taxa that inhabit healthy human body sites as defined in the human
microbiome projects (HMP). The colored rectangles denote phylum/class and genera. Clinical studies of the microbiome will help to elucidate the link between
microbes and the promotion of a large number of diseases and pathological conditions as shown in the figure. The images were adapted from NIH HMP (http://
www.hmpdacc.org/) and National Human Genome Research Institute (https://www.genome.gov/). TORCH, Toxoplasmosis, Oher infections (coxsackievirus, HIV,
syphilis, etc), Rubella, Cytomegalovirus, Herpes simplex.
complex ecosystem is diﬃcult and it is still not easy to deﬁne
how shifts in microbial composition and member abundance
can lead to diseases. Induction of some IBD has been linked to
a reduction of Firmicutes and Bacteroidetes and an expansion
of Proteobacteria. For example, Faecalibacterium prausnitzii,
a prominent member of Clostridium group IV (Firmicutes),
protective and anti-inﬂammatory commensal bacterium, is
frequently reduced in CD patients (Sokol et al., 2008; Sartor and
Mazmanian, 2012). Despite these advances, it should be noted
that microbiota composition varies between diﬀerent locations
in the gastrointestinal tract (Eckburg et al., 2005; Zoetendal et al.,
2008; Arumugam et al., 2011; Cucchiara et al., 2012; Segata et al.,
2012; Lepage et al., 2013). Most studies in the literature have
explored only fecal microbiota. Fecal samples contain between
1,000 and 1,150 bacterial species, and up to 55% are uncultivable
and thus uncharacterized (Zoetendal et al., 2008; Qin et al., 2010;
Segata et al., 2012; Zhou et al., 2014). Our knowledge is especially
limited when it comes to the other parts of the GI tract, a potential
source of uncharacterized microbial species, which is largely due
to sampling constraints.
The dysregulation of the intestinal immune system can
also trigger microbial dysbiosis (Clemente et al., 2012; Sartor
and Mazmanian, 2012; Brown et al., 2013). Many diﬀerent
inﬂammatory diseases are characterized by mutations or loss
of some innate response genes in lymphoid tissues, Paneth
cells, smaller Peyer’s patches and mesenteric lymph nodes
(Clemente et al., 2012; Frantz et al., 2012; Sartor andMazmanian,
2012). The growth of microbiota communities is under control
of distinct subfamilies of host genes encoding antimicrobial
peptides (AMPs). AMPs are the most ancient component of
the innate host response against bacterial infections (Guani-
Guerra et al., 2010; Ostaﬀ et al., 2013). When bacteria colonize
a given human habitat, the expression of AMPs, including α
and β defensins and cathelicidins, is upregulated in order to
limit the spreading of bacteria. The equilibrium between the
immune system and immunoregulatory functions of bacteria
appears to be a delicate balance in which the loss of a
speciﬁc species can lead to an overreaction or suppression
of the innate immune system (Round and Mazmanian, 2009;
Clemente et al., 2012; Sartor and Mazmanian, 2012; Brown
et al., 2013). Intestinal epithelial cells (IECs) form a physical
and immunological barrier that separate luminal bacteria from
underlying immune cells in the intestinal mucosa. IECs and
hematopoietic cells express a variety of receptors called pattern
recognition receptors (PRRs) that mediate the interactions
between the immune system and the commensal microbiota
(Frantz et al., 2012). Toll-like receptors (TLRs) and nuclear
oligomerization domain-like receptors (NLRs) are examples
of PRR that recognize unique microbial molecules named
microbe-associated molecular patterns (MAMPs) including
lipopolysaccharides (LPS), lipid A, peptidoglycans, ﬂagella, and
microbial RNA/DNA. These receptors activate inﬂammasomes
and thereby the production of cytokines TNF-α and IL-
1β (Brown et al., 2013; Sangiuliano et al., 2014). Myeloid
diﬀerentiation factor MyD88 is an adaptor protein that is
essential for TLRs signaling and host-microbial interactions
and tissue homeostasis (Sangiuliano et al., 2014). Mice lacking
MyD88 in IECS (IEC-Myd88−/−mice) display intestinal barrier
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disruption, deﬁciency in the production of pro-inﬂammatory
cytokines and AMPs and overgrowth of several enteric bacterial
pathogens (Frantz et al., 2012). It will be important to understand
when and how dysbiosis and genetic defects in mucosa-IECs
and innate regulatory mechanisms can lead to development of
infectious or inﬂammatory diseases.
Microorganisms synthesize a wide range of low-molecular
weight signaling molecules (metabolites), many of which are
similar to metabolites produced by human cells (Wikoﬀ et al.,
2009). The maintenance of a stable, fermentative gut microbiota
requires diets rich in whole plant foods particularly high
in dietary ﬁbers and polyphenols (Zoetendal et al., 2008).
Under anaerobic conditions, species belonging to the Bacteroides
genus, and to the Clostridiaceae and Lactobacillaceae families,
produce short-chain fatty acids (SCFAs). Acetate (with two
carbons), propionate (with three carbons), and butyrate (with
four carbons) are SCFA used by the epithelial cells of the
colon (colonocytes) and act as a major player in maintenance
of gut homeostasis (Meijer et al., 2010). SCFAs induce the
secretion of glucagon-like peptide (GLP-1) and peptide YY
(PYY), which increase nutrient absorption from the intestinal
lumen. This is a key process in controlling mucosal proliferation,
diﬀerentiation and maintenance of mucosal integrity (Round
and Mazmanian, 2009). Individuals colonized by bacteria
of the genera Faecalibacterium, Biﬁdobacterium, Lactobacillus,
Coprococcus, and Methanobrevibacter have signiﬁcantly less of a
tendency to develop obesity-related diseases like type-2-diabetes
and ischemic cardiovascular disorders (Ley et al., 2006; Le
Chatelier et al., 2013). These species are characterized by high
production of lactate, propionate and butyrate as well as higher
hydrogen production rates, which are known to inhibit bioﬁlm
formation and activity of pathogens, including Staphylococcus
aureus, in the gut (Le Chatelier et al., 2013). Genetic and
diet-induced mouse models of obesity have shown that the
Bacteroidetes/Firmicutes ratio is decreased in obese animals
compared to non-obese animals, which is consistent with what
has been observed in human obese subjects (Ley et al., 2005,
2006; Le Chatelier et al., 2013; Verdam et al., 2013). However,
controversies exist regarding the human data on gut microbiota
composition in relation to obesity (Turnbaugh et al., 2009;
De Filippo et al., 2010; Verdam et al., 2013). The intestinal
microbiota changes in obese mice may increase the intestinal
permeability and inﬂammation locally and in adipose tissues
(Cani and Delzenne, 2011; Kootte et al., 2012). As discussed
in recent studies, the microbial-derived LPS released through
circulation may promote low-grade inﬂammatory process and
metabolic disturbances related to obesity, such as insulin
resistance and type-2 diabetes (Cani and Delzenne, 2011; Kootte
et al., 2012). Despite our currently incomplete understanding of
the mechanisms, there have been high expectations that targeted
changes in microbiota by the rational use of prebiotics and
probiotics might abolish metabolic alterations associated with
obesity (Cani and Delzenne, 2011; Kootte et al., 2012).
Vagina Microbiome
The ﬁrst study based on pyrosequencing of barcoded 16S
rRNA genes of vaginal microbiota performed on samples from
North-American women revealed the inherent diﬀerences within
and between women in diﬀerent ethnic groups (Ravel et al.,
2011). The vaginal microbial composition from three vaginal
sites (mid-vagina, cervix, and introitus) has been compared to
the buccal mucosa and the perianal region in recent studies
(Fettweis et al., 2012; Romero et al., 2014; Vaginal Microbiome
consortium6). These studies have shown that the vagina possesses
over 200 phylotypes and that the most predominant belong
to the phyla Firmicutes, Bacteroidetes, Actinobacteria, and
Fusobacteria (Ravel et al., 2011; Romero et al., 2014). The
vagina has low pH due to secretion of lactic acid and hydrogen
peroxide by Lactobacillus sp. If Lactobacillus decreases under the
eﬀects of antibiotics, Gardnerella vaginalis and Peptostreptococcus
anaerobius, Prevotella sp., Mobiluncus sp. Sneathia, Atopobium
vaginae, Ureaplasma, Mycoplasma, and numerous fastidious
or uncultivated anaerobes can cause bacterial vaginosis (BV).
BV is an ecological disorder of the vaginal microbiota that
aﬀects millions of women annually, and is associated with
numerous adverse health outcomes including preterm birth and
acquisition of sexually transmitted infections, e.g., HIV,Neisseria
gonorrhoeae, Chlamydia trachomatis, and HSV-2 (Kenyon
et al., 2013). Lactobacillus morphotypes predominate in normal
grade 1. BVs grade 3 and higher are characterized by a reduced
number of lactobacilli and increased diversity, especially high
concentration of Gram-negative bacteria and coccobacillus (e.g.,
G. vaginalis and G. mobiluncus) and Peptostreptococcus (Delaney
and Onderdonk, 2001). The results of microbiome studies of the
vagina are showing diﬀerent patterns and imbalances in bacterial
communities associated with BVs, as well as those associated with
non-infectious pathological states that predict increased risk for
infertility, spontaneous abortion, and preterm birth.
Oral Microbiome
Advances in microbiological diagnostic techniques have shown
the complex interaction between the oral microbiota and the
host (Segata et al., 2012; Jiang et al., 2014; Perez-Chaparro
et al., 2014). Bacteria, fungi, archaea, viruses, and protozoa are
part of the oral microbiome. The HMP investigated bacterial
communities in nine intraoral sites: buccal mucosa, hard
palate, keratinized gingiva, palatine tonsils, saliva, sub-and supra
gingival plaque, throat, and tongue dorsum (HumanMicrobiome
Project, 2012a,b). Over 300 genera, belonging to more than
20 bacterial phyla were identiﬁed (Zhou et al., 2013; Jiang
et al., 2014). However, only a limited number of species ﬁnd
proper conditions to colonize the root canal system (Zhou
et al., 2013; Perez-Chaparro et al., 2014). The microbiota of
periodontitis or caries is usually complex consisting of Gram-
negative anaerobic bacteria such as Porphyromonas gingivalis,
Treponema denticola, Prevotella intermedia, Tannerella forsythia,
and Agregatibacter actinomycetemcomitans (Mason et al., 2013;
Jiang et al., 2014). Most early data on the endodontic microbiota
were obtained by culture-based method and it is likely that not-
yet-cultivable and unknown species of bacteria play a role in
oral microbial shift toward a disease (Mason et al., 2013; Zaura
et al., 2014). As expected, deep DNA sequencing data revealed a
6http://vmc.vcu.edu/
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larger number of taxa involved in endodontic infections. Species
of phyla Bacteroidetes, Firmicutes, Proteobacteria, Spirochaetes,
Synergistetes, and Candidatus Saccharibacteria were more
frequently found. All these studies on bacterial diversity in
endodontic infections revealed high inter-subject variability,
indicating the need for further studies using homogenous
diagnosis criteria in a signiﬁcant number of healthy subjects
(Mason et al., 2013; Jiang et al., 2014; Perez-Chaparro et al., 2014).
Skin Microbiome
The skin is the human body’s largest organ, colonized by
over 100 microbial phylotypes, most of which are harmless
or even beneﬁcial to their host (Rosenthal et al., 2011;
Ladizinski et al., 2014; Zhou et al., 2014). Phylotypes, microbial
abundance and diversity diﬀer in relation to skin color,
race, and geographic location (Grice et al., 2009; Rosenthal
et al., 2011). Colonization is inﬂuenced by the ecology
and the epidermis layers of the skin surface. Therefore
it is highly variable depending on topographical location,
endogenous host factors and exogenous environmental factors.
The Actinobacteria phylum is the most abundant on the skin.
Gram-positive Staphylococcus epidermidis and Propionibacterium
acnes are predominant on human epithelia and in sebaceous
follicles, respectively. Propionibacterium acnes colonizes healthy
pores and is responsible for the production of SCFAs and
thiopeptides, which inhibit the growth of Staphylococcus aureus
and Streptococcus pyogenes. However, depending on the host’s
immune system, the overgrowth and clogging of pores allow
subsequent colonization of S. epidermidis and Staphylococcus
aureus. Atopic dermatitis is one chronic inﬂammatory condition
of the skin that occurs in many children and adults (Grice
et al., 2009). Staphylococcus sp. Corynebacterium sp. and the fungi
Candida sp, and Malassezia sp. are also frequently associated
with a number of skin diseases, including atopic dermatitis and
abnormal ﬂaking and itching of the scalp (Grice et al., 2009).
The skin microbiota is under autonomous control of the
local cutaneous immune system, thus it is independent of the
systemic immune response which is modulated by the gut
microbiota (Naik et al., 2012). The major innate mechanism
of antimicrobial defense on the skin consists of AMPs, for
example defensins, cathelicidin LL-37 and dermcidin (Guani-
Guerra et al., 2010). These peptides are emerging as important
tools in the control of skin pathogenic bacteria as well as bacteria
involved in diseases of the lung and gastrointestinal tract. Many
AMPs bind to the phospholipid membrane surfaces, forming
ion-channels and pores causing leakage and cell death (Guani-
Guerra et al., 2010; Ostaﬀ et al., 2013). However, their speciﬁc
immunomodulatory roles in innate immune defense against
bacterial and viral infection remain poorly understood (Ostaﬀ
et al., 2013; Wang, 2014). An enhanced understanding of the skin
microbiome is necessary to gain insight into AMPs and innate
response in human skin disorders. The cutaneous inﬂammatory
disorders such as atopic dermatitis, psoriasis, eczema, and
primary immunodeﬁciency syndromes have been associated with
dysbiosis in the cutaneous microbiota. The skin commensals
promote eﬀector T cell response, via their capacity to control
the NF-κB signaling and the production of cytokines TNF-α and
IL-1β (Hooper et al., 2012). The binding of the skin microbiota
components to TLRs or NLRs allows a sustainable homeostasis
toward innate and adaptive immunity within a complex epithelial
barrier throughout distinct topographical skin sites.
Placenta Microbiome
Historically, the fetus and intrauterine environment were
considered sterile. However, the ﬁrst proﬁle of microbes in
healthy term pregnancies identiﬁed a unique microbiome niche
in normal placenta, composed of non-pathogenic commensal
microbiota from the Firmicutes, Tenericutes, Proteobacteria,
Bacteroidetes, and Fusobacteria phyla (Aagaard et al., 2014).
This study describes the microbial communities of 320
placental specimens and, despite the expected diﬀerences
between individuals, the taxonomic classiﬁcation of the placental
microbiome bears most similarity to the non-pregnant oral
microbiome, in particular to those associated with tongue,
tonsils, and gingival plaques. One predominant species was
Fusobacterium nucleatum, a Gram-negative oral anaerobe. E. coli
was also found in placenta; however, it is not present in the
oral microbiome (Aagaard et al., 2014). The authors suggested
a possible hematological spread of oral microbiome during early
vascularization and placentation. The pathways related with the
metabolism of cofactors and vitamins were the most abundant
among placental functional gene proﬁles, which is diﬀerent from
the metabolic pathways found in other body sites (Aagaard et al.,
2014).
The balance of the diﬀerent microbe species in and on
the human body changes throughout life and particularly
in diﬀerent stages of pregnancy (Qin et al., 2010; Human
Microbiome Project, 2012a,b). It is well known that preterm
delivery (<37 weeks) causes substantial neonatal mortality
and morbidity (DiGiulio et al., 2008). Placentas from normal
deliveries and preterm deliveries contained diﬀerent populations
of microbial species (Groer et al., 2014). The gram-negative
bacillus Durkholderia was associated with preterm delivery and
the gram-positive, rod-shaped, facultative anaerobic bacteria
Paenibacilluswith term delivery (Aagaard et al., 2014). Consistent
with other studies, an enrichment in Streptococci, Acinetobacter
and Klebsiella was also demonstrated in women with history of
antenatal infection (Aagaard et al., 2014).
The presence of diﬀerent microbes in amniotic ﬂuid,
umbilical cord blood, meconium (ﬁrst stool), placental and
fetal membranes suggested the existence of various routes
and mechanisms by which bacteria from diﬀerent microbiota
translocate to placenta and babies (DiGiulio et al., 2008). Studies
in mice have demonstrated the placental transmission from
mother’s oral microbiota (Fardini et al., 2010). Many of these
organisms are transmitted to babies during nursing. Babies
born vaginally have more diverse gut microbial communities
similar to their mother’s vaginal microbiota, while microbiomes
of babies delivered by Cesarean section are similar to skin
microbiota (Dominguez-Bello et al., 2010). The lack of exposure
to maternal vaginal microbiome might explain why cesarean
section babies are at greater risk of developing type 1 diabetes,
celiac disease, asthma, and obesity (DiGiulio et al., 2008;
Dominguez-Bello et al., 2010). Breastfed babies’ microbiome is
Frontiers in Microbiology | www.frontiersin.org 6 October 2015 | Volume 6 | Article 1050
Belizário and Napolitano Human microbiomes
enriched with Lactobacillus and Biﬁdobacterium species whereas
microbiome of babies fed with formula/solid food are enriched
with Enterococci, Enterobacteria, Bacteroides, Clostridia, and
Streptococci (Guaraldi and Salvatori, 2012; Palmer et al., 2012;
Thompson et al., 2015). The transition from breast milk to
solid foods is associated with acquisition of a more adulthood-
like microbiome; however, infectious diseases, antibiotic use
and the characteristics of the diet can interfere with babies’
microbiota composition (Thompson et al., 2015). Together, these
ﬁndings emphasize the need for further studies on placental
microbiome for elucidating more mechanisms to be explored in
the prevention and treatment of babies from preterm birth and
other diseases.
Microbiota-based Pharmaceuticals
Metagenomics has proven to be a powerful tool in determining
the diversity and abundance of microbes in the human body.
The microbiome databases have been explored as sources of
interesting targets to drug development (Cani and Delzenne,
2011; Collison et al., 2012; Haiser and Turnbaugh, 2012;
Carr et al., 2013; Wallace and Redinbo, 2013). Therapeutic
interventions in the microbiome can be directed against
molecular entities, such as essential and antibiotic resistance
genes to quorum sensing systems components used to control
microbial networking behaviors, including the chemical
communication and production of virulence factors (Collison
et al., 2012). In the next sections, we will present and discuss
strategies to discover novel antimicrobial targets as well as
dietary interventions and microbial modiﬁcation genetic tools to
eliminate pathogenic microorganisms and to control dysbiosis.
Targeting Essential Genes
Searching of essential genes for bacterial growth and viability is
the ﬁrst step for identifying potential drug targets (Wallace and
Redinbo, 2013). Computational analyses can provide candidate
targets in microbial community of pharmacological signiﬁcance
for controlling bacterial species involved in chronic diseases,
metabolic, and cardiovascular diseases as well as drugmetabolism
(Collison et al., 2012). The metagenomic databases are critical
for constructing gene and protein networks and an initial
framework for drug target screening (Collison et al., 2012; Carr
et al., 2013; Manor and Borenstein, 2015). Several bioinformatics
approaches have been used to identify microbial gene essentiality
and putative new classes and functions for unique microbial
genes in the metagenomic databases. HUMAnN is a program
for metagenomic functional reconstruction to directly associate
community functions with habitat and host phenotype. This
program has been used to compare functional diversity and
organismal ecology in the human microbiome (Abubucker et al.,
2012). About 20% of all genes in a strain are essential and
this has gained interest in drug discovery research (Christen
et al., 2011). In vitro transposition and genetic transformation
of the wild-type bacteria using a transposon library is a
reliable experimental approach to uncover gene essentiality
(van Opijnen et al., 2009). ESSENTIALS is another software
for rapid analysis of high throughput transposon insertion
sequencing data and discovery of essential genes (Zomer et al.,
2012).
The majority of unique targets found in microbes’ genomes
are genes responsible for the metabolism of carbohydrates,
amino acids, xenobiotics, methanogenesis, and the biosynthesis
of vitamins and isoprenoids. These genes are either non-
homologous or orthologous to those encompassed in human
genome. Vitamin biosynthetic pathways constitute a major
source of potential drug targets. Most bacteria synthesize
thiamine de novo, whereas humans depend on dietary uptake.
Folic acid (vitamin B9) is an indispensable cofactor, which plays
a key role in the methylation cycle and in DNA biosynthesis.
Enzymes of the folate biosynthesis pathway, for example,
dihydrofolate reductase, have been an attractive pharmaceutical
targets for inhibiting folate synthesis. Sulfanilamide and
trimethoprim are examples of eﬀective antimicrobials used
in a broad range of infectious diseases. Niacin (vitamin B3)
participates in the biosynthesis of nicotinamide adenine
dinucleotide (NAD+), a coenzyme essential in electron transport
reactions in cell metabolism processes. Bacterial NAD+ kinases
have been explored as targets for inhibiting bacterial growth.
Methionine is not synthesized de novo in humans, and is supplied
by diet. In contrast, most bacteria need to synthesize methionine
to survive. S-adenosylmethionine synthetase, a key enzyme in
methionine biosynthesis, is one drug target whose great potential
has been explored against various pathogens. New drugs, for
example platensimycin and platencin, that inhibit the microbial
fatty acid synthesis (FAS) pathway by targeting key FAS enzymes
have been successfully developed (Parsons et al., 2014). A recent
survey identiﬁed 127 orthologous groups conserved in both
human and human commensal gut microﬂora that are not
suitable targets for drug development. However among these, the
20 aminoacyl-tRNA synthetases (aaRSs), which encode essential
enzymes for protein synthesis, can be used since bacterial and
eukaryotic AaRS have diﬀerent speciﬁcity for tRNAs (Ochsner
et al., 2007; Mobegi et al., 2014). These are only few examples of
attractive targets for drug development; however, metagenomic
data will open new frontiers for discovery of essential genes.
Targeting Antibiotic Resistance Genes
The structure of the microbial community is maintained by
speciﬁc microbial communication, cell signaling through cell-
to-cell contact, metabolic interactions, and quorum sensing
(Wright, 2010). Species within a bacterial community are
either susceptible or resistant to epithelial innate AMPs and/or
chemical antibiotics (Seo et al., 2010; Wozniak and Waldor,
2010; Sommer and Dantas, 2011). Bacterial genomes acquired
resistance and metabolic genes from mobile genetic elements
(MGE), including conjugative transposons, also called integrative
conjugative elements (ICE), which are horizontally transferred
by bacteriophages and plasmids (Wozniak and Waldor, 2010).
Antibiotic resistance genes encoded in microbial genomes
include multidrug eﬄux transporters, tetracycline resistance
genes, vancomycin resistance genes, and beta-lactamases.
In addition, a number of microbial genes and products,
including bacteriocins, lysins, holins, restriction/modiﬁcation
Frontiers in Microbiology | www.frontiersin.org 7 October 2015 | Volume 6 | Article 1050
Belizário and Napolitano Human microbiomes
endonuclease systems, and other virulence factors contribute
to resistance to antibiotics (Dawid et al., 2007; Seo et al., 2010;
Wozniak and Waldor, 2010; Smillie et al., 2011). Targeted
(PCR-based) and functional metagenomic approaches have
been used to track the presence of resistance genes or their
families in diﬀerent ecosystems (Mullany, 2014). A method
to speciﬁcally trap plasmids containing antibiotic resistance
genes called transposon-aided capture (TRACA) has been
developed (Jones and Marchesi, 2007; Mullany, 2014). In this
method, the plasmids are tagged with transposons that contain
a selectable marker and a replication origin, which facilitate
acquisition of plasmids from the human gut metagenomic DNA
extracts, and subsequent maintenance and selection in an E. coli
host.
Most of the antibiotics used to ﬁght bacterial infections today
are derived from soil microbes. Penicillin, the ﬁrst true antibiotic,
came from the soil fungus Penicillium (Kardos and Demain,
2011). To investigate the role of soil microbiota as a reservoir
of genes encoding antibiotic resistance in the metagenomic data
set, the ORFs found on contigs and on unassembled reads were
compared with 3,000 known antibiotic resistance genes (Forsberg
et al., 2014). It was concluded that most of the identiﬁed soil
bacteria resistance genes were not typically close to known
human pathogen resistance genes, suggesting little sharing
between soil and gut bacterial species. A study on the microbiome
of uncontacted Amerindians, members of a Yanomami isolated
village living in the Amazon region has revealed the highest
diversity of bacteria and genetic functions in fecal, oral, and
skin bacterial microbiome ever reported compared with the US
group (Clemente et al., 2015). Despite their isolation and no
known exposure to commercial antibiotics, they carry functional
antibiotic resistance genes with over >95% amino acid identity
to those that confer resistance to semisynthetic and synthetic
antibiotic monobactam and ceftazidime (Clemente et al., 2015).
This ﬁnding provided important insights into howwesternization
impacts on the heritability of the microbiome among populations
(Yatsunenko et al., 2012). There is evidence suggesting that
exposure to microbes from animal gut microbiomes and within
our indoor spaces (house, oﬃce, schools, cars, etc.) may become
new sources for antibiotics and antibiotic resistance genes
to human populations (Wright, 2010; Sommer and Dantas,
2011; Forslund et al., 2013). These discoveries emphasize the
importance of continued functional investigations on antibiotic
resistance reservoirs in metagenomic data from isolated ancestral
and modern populations with a given disease.
Targeting Quorum Sensing Systems
The term “Quorum Sensing” (QS) indicates systems used by
bacteria to communicate with each other in order to synchronize
their gene expression activities and behave in unison as a group
(Miller and Bassler, 2001; Waters and Bassler, 2005; Hense
and Schuster, 2015). This mechanism controls the synthesis of
secreted products, disease-causing virulence factors, and many
metabolites, including bacterial antibiotics that target competing
bacteria, and substances that suppress the immune system
(Miller and Bassler, 2001; Waters and Bassler, 2005). Thus, an
alternative to killing or inhibiting growth of pathogenic bacteria
is targeting these key regulatory systems (Finch et al., 1998;
Defoirdt et al., 2010). Metagenomic studies have identiﬁed the
genetic and phenotypic diversity of quorum-sensing systems that
co-evolved with pathogenic species (Joelsson et al., 2006; Kimura,
2014). QS system was ﬁrst described in marine bacteria Vibrio
harveyi and V. ﬁscheri, which use LuxI and LuxR proteins to
control the expression of the luciferase enzyme for emitting
luminesce upon reaching a critical mass or “quorum” (Nealson
and Hastings, 1979). These bacteria secrete in the extracellular
environment a small molecule, an acylated homoserine lactone
(AHL), called autoinducer 1 (AI-1), to communicate with
members of the same species (intraspeciﬁc communication;
Miller and Bassler, 2001; Waters and Bassler, 2005; Ng and
Bassler, 2009). After its discovery in marine bacteria, QS
systems have been identiﬁed in more than 70 diﬀerent bacterial
species, including Streptococcus pneumoniae, Bacillus subtilis,
and Staphylococcus aureus (Miller and Bassler, 2001; Waters
and Bassler, 2005; Ng and Bassler, 2009). The QS systems
control not only bioluminescence, but also other cooperative
processes such as sporulation, conjugation, nutrient acquisition,
bioﬁlm formation, bio-corrosion, and antibiotics and toxins
(Waters and Bassler, 2005; Kimura, 2014; Hense and Schuster,
2015). Remarkably, bacteria not only can communicate with
members of the same species, but they are also able to sense
the presence of diﬀerent species in a community (interspeciﬁc
communication). This interspeciﬁc communication is performed
using a second type of autoinducer (AI-2). Thus, while each
bacterial species has its own AI-1 to talk intraspeciﬁcally, AI-
2 is common to all Gram-negative and Gram-positive bacteria.
In fact AI-2 is not a single molecule but rather it refers to a
group of molecules belonging to the family of interconverting
furanones derived from 4,5-dihydroxy-2,3-pentanedione (DPD),
whose biosynthesis is under the control of the enzyme LuxS
(Xavier and Bassler, 2003). Development of novel compounds
able to disrupt QS mechanisms has been carried out in recent
years. For example QS quenching enzymes like lactonases
and acylases are able to degrade acylated homoserine lactone
(Dong and Zhang, 2005). A series of compounds, named
halogenated furanones produced by many microbial species,
mostly belonging to the Proteobacteria, can interfere with AHL
and AI-2 QS pathways in Gram-negative and Gram-positive
bacteria (Maneﬁeld et al., 2002; Rasko et al., 2008; Kayumov
et al., 2014). Identiﬁcation of the chemical signals, receptors,
target genes, and mechanisms of signal transduction involved in
quorum sensing are essential to our understanding how bacterial
cell-cell communication may be used in preventing colonization
by pathogenic bacteria. More data from metagenomic and
metabolomics studies will help to decode the bacterial cross-
talk and microbiome-immune system interplay, and particularly,
distinctive regulatory mechanisms.
Targeting Dysbiosis
Fecal Transplantation
Antibiotics have been used to treat infectious diseases over the
past century. However, it is clear that antibiotic treatment can
render individuals more susceptible to infections (Dethlefsen
et al., 2008; Forslund et al., 2013). High doses and frequent
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use of antibiotics can disrupt and destabilize the normal
bowel microbiota, predisposing patients to develop Clostridium
diﬃcile infections. Up to 35% of these patients develop a
chronic recurrent pattern of disease. Fecal bacteriotherapy is
the transplantation of liquid suspension of stool from a donor
(usually a family member) and has been used successfully in
severe cases of recurrent C. diﬃcile relapse (Gough et al., 2011;
Rupnik, 2015). However, many problems exist with this therapy
since it can increase the risks of transmitting other pathogens
(Brandt and Reddy, 2011).
Fecal transplantation studies in mice showed that transferring
the microbiota from lean and fat mice to germ-free mice induces
greater weight gain in those receiving the microbiota from fat
donors (Ley et al., 2006). The discovery of the link between
lean-associated microbiome has opened new possibility of using
transplanted microbiota to treat metabolic disorders in humans.
Probiotics and Prebiotics
Probiotics are deﬁned as live microorganisms that ultimately
improve the balance of the intestinal ﬂora, thus fostering healthy
gut functions through a healthy gut microbiome (reviewed in
Gareau et al., 2010; Whelan and Quigley, 2013). There are several
in vitro assays to validate the actual in vivo eﬃcacy of probiotic
microorganisms, which include speciﬁc biological criteria, such
as resistance to low gastric pH and capacity to reach the intestines
alive to exert beneﬁcial eﬀects on the human body (Papadimitriou
et al., 2015). Probiotic microorganisms are mainly lactic acid-
producing bacteria of Lactobacillus and Biﬁdobacterium genera.
Other microorganisms, such as the yeast Saccharomyces boulardii
and the bacteria E. coli Nissle 1917, Streptococcus thermophilus,
F. parausnitzii and Bacillus polyfermenticus have also been
investigated. The beneﬁcial therapeutic eﬀects and mechanisms
of action of Lactobacilli and biﬁdobacteria in patients with
gastrointestinal diseases have long been demonstrated (Ng
et al., 2009). These probiotics can prevent or ameliorate clinical
symptoms of irritable bowel syndrome, inﬂammatory and
necrotizing enterocolitis and acute diarrhea (Ng et al., 2009;
Gareau et al., 2010; Whelan and Quigley, 2013). It was found
that they could regulate the balance of intestinal microbiota
by physically blocking the adhesion of pathogenic species onto
epithelial cells. This is directly mediated by means of increases
in the production of a mucosal barrier by goblet epithelial cells
(Etzold et al., 2014). In addition, they can regulate epithelial
permeability by enhancing the formation of tight-junctions
between cells (Ng et al., 2009). Their immune-modulatory
eﬀects are associated with a decrease in the production of
pro-inﬂammatory cytokines, as well as the microbial peptides
bacteriocins (Ng et al., 2009; Whelan and Quigley, 2013).
The use of probiotics is not limited to gastrointestinal
disorders. Studies evaluating their application in dermatology,
urology and dentistry have been increasing (Vuotto et al.,
2014). Biﬁdobacterium biﬁdum has been used in the prevention
and treatment of infantile eczema. Intra-vaginal administration
of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14
were shown to have a positive eﬀect on the prevention of
recurrent BV and candidiasis (Anukam et al., 2006; Vuotto
et al., 2014). Consumption of probiotics can be eﬀective in the
prevention of dental caries and periodontal diseases (Pandey
et al., 2015). The continuous consumption of Yakult’s L. casei
strain Shirota (LcS), one of the most popular probiotics, in
adequate amounts, may reduce the risk of cancers by modulating
immune function (Ishikawa et al., 2005). Finally, the treatment
of obese mice with Biﬁdobacterium infantis was shown to reduce
the production of pro-inﬂammatory cytokines and white adipose
tissue weight (Cani et al., 2007). The eﬀect of the endogenous
host microbiota on obesity and beneﬁcial role of probiotics
including L. rhamnosus and gasseri and Biﬁdobacterium lactis
in the treatment of adiposity and obesity has been reviewed
elsewhere (Mekkes et al., 2014). This is a new area under intense
investigation.
Prebiotics are functional food ingredients that can change
the composition and/or the activity of the colonic ﬂora
(Roberfroid, 2000; Roberfroid, 2007; Brownawell et al., 2012).
The dietary supplementation with prebiotics can promote
the growth of beneﬁcial bacteria such as lactobacilli and
biﬁdobacteria strains (Roberfroid, 2000, 2007). Poorly digestible
carbohydrates (ﬁbers), such as resistant starch, non-starch
polysaccharides (e.g., celluloses, hemicelluloses, pectins, and
gums), oligosaccharides and polyphenols are resistant to
gastric acidity, gastrointestinal absorption, and non-digestible by
hydrolysis by mammalian enzymes. Colonic bacteria through
carbohydrate hydrolyzing enzymes and fermentation produce
hydrogen, methane, carbon dioxide, and SCFA, which can aﬀect
host energy levels and gut hormone regulation (Slavin, 2013).
The most commonly used prebiotics are fructo-oligosaccharides
(FOS) and trans-galacto-oligosaccharides (TOS), for example
inulin (Roberfroid, 2000). However, not all dietary carbohydrates
are prebiotics (Roberfroid, 2007). Mixtures of probiotic and
prebiotic ingredients have been used to selectively stimulate
growth or activity of health-promoting bacteria. In conclusion,
it appears that the therapeutic use of pro- and prebiotics will
ﬁnd more applications in the near future when large-scale clinical
trials and metagenomic surveys will determine which microbes
are active, which are damaged, and which may respond to a given
prebiotic, probiotic or synbiotic (synergic association of probiotic
and prebiotic) at the genomic level (Nagata et al., 2011).
Phage Therapy and CRISPRs
Phage therapy consists of using bacterial viruses bacteriophages,
(also known as phages) as antimicrobial agents (Sulakvelidze
et al., 2001; Abedon, 2014). Bacteriophages attach to speciﬁc
receptors present in the host membrane and then inject their
genetic material into the bacterium. Viral proteins are then
synthetized using the host’s translational machinery. Phage
infection can result in lysis, lysogeny or resistance. Lytic
bacteriophages induce host cell death and breakdown in order
to spread the infection whereas lysogenic (or temperate) phages
insert their genome into the host DNA. Resistance may be
acquired during replicative cycles by gene transposition or
recombination.
Phage therapy can potentially have beneﬁcial impact on
human microbiomes and host health (Koskella and Meaden,
2013). The host speciﬁcity greatly limits the types of bacteria
that will enter into contact with a particular phage, therefore
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FIGURE 2 | Possible future therapeutic approaches to control dysbiosis. Disturbances in the ecological community of commensal, symbiotic, and pathogenic
microorganisms may favor dysbiosis. This leads to increased bacterial translocation and/or release of microorganism-associated molecular patterns (MAMPs), which
activate Toll-like receptors (TLRs) in several cell types. Local and body-wide immune system activities promote inflammation, which ultimately leads to chronic
diseases. Novel therapeutic approaches like phage therapy, disruption of Quorum Sensing and the use of the biotechnological tool CRISPR/Cas9 to edit microbial
genomes have the potential to target specific bacterial taxa thus helping to re-establish homeostasis and microbiome balance.
avoiding the elimination of non-pathogenic species (Koskella and
Meaden, 2013). However in order to choose a speciﬁc phage to
use as a therapeutic agent, it is necessary to know the pathogen
causing a given disease. When this is not the case, the use of a
cocktail of diﬀerent species of phages would broaden the range
of action but could also have a possible negative eﬀect on the
microbial communities (Chan et al., 2013). The synergistic use
of phages and low dose of antibiotics, a strategy named Phage-
Antibiotic Synergy (PAS), could be useful in certain clinical
situations (Comeau et al., 2007).
Bacteria have evolved various mechanisms of defense against
phage infections, which act at diﬀerent levels. In fact they
can prevent phage attachment by mutation/loss of membrane
receptors or block phage DNA entry with the aid of speciﬁc
membrane proteins. Furthermore, Bacteria and Archaea
developed an intrinsic innate immunity mechanism, which
allows them to remember phage infection by capturing short
DNA sequences from phage genetic material. These viral
sequences are integrated as spacer sequences into their own
chromosome, speciﬁcally into an array of repeated sequences
called Clustered Regularly Interspaced Short Palindromic
Repeats or CRISPR, with the help of the proteins encoded by Cas
(CRISPR-associated) family of genes (Garneau et al., 2010; van
der Oost et al., 2014).
CRISPR loci consist of short (∼24–48 nucleotides) repeats
separated by similarly sized, unique spacers found in genomes
of Archaea (∼90%), and Bacteria (∼40%) (Garneau et al.,
2010; van der Oost et al., 2014). Cas genes encode a large
and heterogeneous family of proteins with functional domains
typical of nucleases, helicases, polymerases, and polynucleotide-
binding proteins. Upon invasion, the host organism samples
and integrates in its genome short fragments of the foreign
DNA, called protospacers, thus creating immunity against that
particular infective agent. The protospacer is ﬂanked by the
repeated regions, and transcribed with them into a CRISPR-
RNA (crRNA), which guides speciﬁc nucleases to a target DNA
containing regions complementary to the protospacer. Upon
recognition, nucleases cleave invasive DNA preventing it to
replicate and blocking infection. Three diﬀerent types and eleven
subtypes of CRIPSR/Cas system can be classiﬁed based on their
Cas protein repertoire and mechanisms of action (Plagens et al.,
2015). A detailed list of type I, II, and III CRISPR-Cas systems
is also available at the CRISPRdb website7. Type I systems are
characterized by the molecular machinery named a Cascade
complex (CRISPR-associated complex for antiviral defense)
which displays nickase and exonuclease activities. Type III
systems are characterized by the presence of Cas10 (the signature
protein) and associated proteins. The systems are subclassifed
as type III-A (CSM) and type III-B (CMR), depending on their
speciﬁcity for DNA or RNA targets. In addition, types I and III
share a variable number of repeat associated mysterious protein
(RAMP) subunits (Rouillon et al., 2013; Plagens et al., 2015).
7http://crispr.u-psud.fr/
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FIGURE 3 | Actions and molecular approaches aiming to protect the environmental and human microbial ecosystems. The measurements of ecological,
phylometagenomic, and microbial metabolic variations in the microbiomes require a specialized and complex set of knowledge. Collaboration between universities,
research entities, non-governmental organizations (NGO), and the pharmaceutical industry professionals are key for evaluating both biological and pharmaceutical
impacts in the ecosystems and elucidating the mechanism-of-action of new compounds in the host and its microbiomes. The utility of metagenomic functional
reconstruction for direct association of community functions with habitat and host phenotype will be critical for proper study designs and production of greener
pharmaceutical products for future personalized medicine.
Type II is the simplest CRISPR-Cas system that is
characterized by the presence of dsDNA endonuclease Cas9
and the transactivating CRISPR-RNA (tracrRNA). The tracrRNA
anneals with the invariable regions of mature crRNA creating
RNA heterodimers which, in turn, forms a nucleoprotein
complex with Cas9, guiding it to the target DNA. Cas9
recognizes and binds to a speciﬁc 5′-NGG-3′ motif, called
protospacer adjacent motif (PAM). Then the complex searches
for a sequence complementary to the spacer portion of crRNA.
Cas9 contains two nuclease domains, namely RuvC and HNH,
and produces a double strand break in the target. Subsequently,
cleaved DNA becomes a substrate of the bacterial DNA repair
mechanisms, either non-homologous end joining (NHEJ) or
homologous recombination (HR). NHEJ is an imperfect repair
system and may cause insertion or deletion (indels) of base
pairs, as well as single nucleotide polymorphisms (SNPs).
However, high-ﬁdelity HR repair may occur if a sequence
complementary to the cleaved fragment is provided. The relative
simplicity of the mechanism of action and the peculiarities of
Cas9 make the CRISPR/Cas9 system an ideal tool for a vast
assortment of procedures, particularly for genomic editing
(reviewed in Ma et al., 2014; Selle and Barrangou, 2015;
Xiao-Jie et al., 2015). A considerable amount of work in this
ﬁeld has been already done in diﬀerent organisms, especially
eukaryotes, using engineered versions of CRISPR/Cas9. On the
other hand, despite its enormous potential, manipulation of
bacterial genomes by CRISPR/Cas9 has so far been scarcely
executed (Selle and Barrangou, 2015). CRISPR/Cas9 can be
used to selectively deplete a given bacterial community of
a particular harmful strain or species (Vercoe et al., 2013;
Gomaa et al., 2014; Yosef et al., 2015). It has been shown
that there is an inverse correlation between the presence of
CRISPR loci and acquired antibiotic resistance in Enterococcus
fecalis (Palmer and Gilmore, 2010), indicating that the use of
antibiotics may increase the ability of bacteria to acquire drug
resistance-encoding plasmids. CRISPR/Cas9 system can be
used to introduce speciﬁc mutations into essential, antibiotic
resistance, and virulence genes. It has been already shown that
by providing in trans a DNA (linear or plasmid) homologous
to the target sequence, it is possible to introduce very speciﬁc
mutations to the desired target (Marraﬃni and Sontheimer,
2008; Jiang et al., 2013; Yosef et al., 2015). Also CRISPR/Cas9 has
the potential to directly modulate the expression of particular
genes. An engineered version of Cas9 lacking the nuclease
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activity but still retaining its binding capacity (dCas9) has already
been created to repress bacterial transcription by binding to
promoter regions or within a ORF, thus blocking transcriptional
initiation and elongation, respectively. dCas9 can also be fused
to regulatory domains in order to switch on/oﬀ the expression
of speciﬁc genes (Bikard et al., 2013; Qi et al., 2013). In the
near future the engineering of commensal bacteria with improved
properties using a CRISPR/Cas systemmay constitute an eﬀective
vaccination tool in public health for prevention of diseases.
However, despite great advances, still much work needs to
be done in order to improve target speciﬁcity and delivering
eﬃciency.
A more complete perspective on how phage therapy and
CRISPR/Cas9 systems can be employed to combat pathogenic
species within our bodies, especially antibiotic-resistant bacterial
pathogens needs the expansion of in vitro, ex vivo, and in
silico approaches (Fritz et al., 2013). Several publicly available
methods for hit-speciﬁc retrieval of protospacers in the reference
microbiomes have already been developed (Bi et al., 2012). Over
123,003 protospacers have been predicted based on 690 phage
genomes (Zhang et al., 2013). The functional exploration of
pathogen-speciﬁc bacteriophages and gene therapy depends on
development of relevant animal models including transgenic
and bacteria-free animals (Fritz et al., 2013). Finally, we will
need to conﬁrm the results in the proof-of-concept in well-
designed clinical trials. In Figure 2, we graphically summarize
some of the pharmacological approaches discussed in this
article.
Ecopharmacology
To assess the interaction of the human body with
pharmaceuticals, we need to understand the complex relationship
between ecology, physiology, and pharmacology (Rahman
et al., 2007; Flintoft, 2012; Haiser and Turnbaugh, 2012).
From pharmacogenomic studies it is clear that sequence
variations in drug target proteins, drug-metabolizing enzymes,
and drug transporters can alter drug eﬃcacy, produce
side eﬀects, causing variable drug responses in individual
patients (Wilson and Nicholson, 2009). Microorganisms
participate in a very wide range of biotransformations,
including hydrolysis, and processing of glutathione conjugates
of xenobiotics excreted in the bile (Johnson et al., 2012).
Hence, the determination of the genetic variability of
human microbiomes has potential to predict the eﬃcacy,
bioavailability and individual response variability in drug
therapy.
Finally, further studies are needed to elucidate whether the
vast number of functional microbiota gene-products exerts
unknown oﬀ-target eﬀects and how they can negatively or
positively aﬀect drug responses. These are the major research
challenges for exploring the potential of metagenomics to better
understand microbial ecology and to translate the molecular
and genomic data into pharmacomicrobiomics (Saad et al.,
2012). According to this new ecological paradigm, competency
in knowledge, skills, and attitudes as well as integrated
environmental conscience and social responsibility are essential
for professionals who will in the future create and develop a new
generation of green and sustainable pharmaceutical products, as
shown in Figure 3.
Conclusion and Perspectives
Recent advances in microbiome sequencing projects revealed the
high complexity of microbial communities in various human
body sites. They have conﬁrmed the critical roles of the human-
microbiota ecosystems in health-promoting or disease-causing
processes. These studies have highlighted the unexpected and
wide-ranging consequences of eliminating certain bacteria living
in our body.
While the natural variation of the human microbiota has yet
to be fully determined, the annotation and analyses of a large
number of human microbiomes have shown that the presence
or absence of speciﬁc microbial species categorizes human
individuals based on enterotypes. It is likely that cultivated
and uncultivated microbes will contribute to discovering new
fundamental biomarkers for speciﬁc human disorders and that
they may become better discriminatory tools than human-based
ones.
Changes in the stability and dynamic of numerous microbial
communities have been associated with several diseases,
including type II diabetes, obesity, fatty liver disease, irritable
bowel syndrome, and IBDs and even certain cancers. However,
further studies need to be done in order to conﬁrm whether low
bacterial diversity increases the chances to develop such diseases
and metabolic perturbations.
The use of antibiotics compromises genome defense and
increases the ability to acquire antibiotic resistance. Prebiotics,
probiotics, synbiotics, phage therapy, quorum sensing systems,
and CRISPR/Cas systems have been proposed as tools to control
and modulate microbial communities. Engineering of pathogen-
speciﬁc bacteriophages and production of pharmaceuticals based
on our own body’s microbiome will be possible and fully
explored in the near future. The use of novel pharmaceuticals
and nutraceuticals to modulate microbial colonization and
development of a healthy gut microbial community in early
childhood will support healthy adult human body functions and
prevent the occurrence of several diseases.
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